Engineered CD8 Polypeptides Enhance T Cell Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for manufacturing T cells with enhanced cytotoxic activity for immunotherapy are limited in effectiveness.
Innovation Solution
The development of CD8 polypeptides comprising specific domains and sequences, which are used to modify T cells for enhanced cytotoxic activity, are co-expressed with T cell receptors or CAR-T in T cells for adoptive cell therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for manufacturing T cells are used, then the process is relatively simple, but the cytotoxic activity and efficacy are limited
Solution Approach 1:
The patent combines multiple functional domains into a single engineered CD8 polypeptide structure. The CD8α chain includes an immunoglobulin-like domain for MHC binding, a stalk region for structural support, a transmembrane domain for membrane anchoring, and a cytoplasmic domain for signaling. This merging of multiple functional elements into one integrated polypeptide enhances T cell cytotoxic activity while providing a standardized manufacturing approach.
Solution Approach 2:
The engineered CD8 polypeptide functions as a composite molecular structure combining different functional regions with distinct roles. The immunoglobulin-like domain provides antigen recognition capability, the stalk region provides structural stability, the transmembrane domain provides membrane integration, and the cytoplasmic domain provides signaling function. This composite structure achieves enhanced cytotoxic activity through the synergistic combination of these functional elements.
2Productivity
If T cells are modified with engineered CD8 polypeptides, then cytotoxic activity is enhanced, but the manufacturing process becomes more complex
Solution Approach 1:
The engineered CD8 polypeptide is designed with distinct modular domains that can be independently optimized and characterized. The immunoglobulin-like domain, stalk region, transmembrane domain, and cytoplasmic domain are segmented functional units that can be separately analyzed for their contributions to T cell function. This segmentation facilitates systematic optimization while providing a clear framework for manufacturing quality control.
Solution Approach 2:
The patent employs specific parameter optimizations in the CD8 polypeptide structure, including sequence identity thresholds (at least 80%, 85%, 90%, 95%, 98%, or 99% identity to reference sequences), domain boundary definitions, and structural configuration parameters. These parameter specifications enable standardized manufacturing while achieving enhanced cytotoxic activity through optimized molecular characteristics.
Data Source
AI summary
The present disclosure relates to T cells capable of co-expressing T cell receptors (“TCR”) together with CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods thereof.